Nav: Home

Improving diagnosis leads to better outcomes in patients with inflammatory bowel disease

February 07, 2019

Las Vegas, NV (Feb. 7, 2019) -- It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Currently, there are no cures for these diseases. For many patients the path to diagnosis and effective treatment is long and arduous, leading to delayed treatment and increased complications.

Studies being presented at the Crohn's & Colitis Congress -- a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, from Feb. 7-9 -- reinforce the need for and highlight advances towards improved diagnosis of patients with IBD.

Most patients wait a year or more for IBD diagnosis, while their disease progresses

Study Title: Delayed Diagnosis of Crohn's Disease is Common and Associated with Increased Risk of Disease Complications

* Z. Gallinger, Mount Sinai Hospital, Toronto, Ontario, et al.

Significance: Diagnostic delay in IBD patients is associated with increased risk of disease complications. Utilizing IBD Partners, a validated online cohort of IBD patients, a survey assessed self-reported diagnostic delay and perceived reasons for delay. Overall, 68 percent of patients reported delayed diagnosis -- with Crohn's patients more likely than ulcerative colitis patients to report delays. An uncertain or wrong initial diagnosis were the most commonly reported reasons for delay. Prolonged delay, greater than two years, is significantly associated with poor outcomes. The study supports the need to further investigate ways to identify approaches to mitigate the delay.

New biomarker predicts patient prognosis, could make personalized IBD therapy a reality

Study Title: A Blood-based Prognostic Biomarker in Inflammatory Bowel Disease; Towards Personalised Medicine in IBD

* P.A. Lyons, Cambridge Institute of Medical Research

Significance: The course and severity of IBD is unique to the individual patient and varies substantially. The absence of a widely-accepted, predictive diagnostic in clinical practice is a hindrance to disease management, with the potential for over- or under-treatment. This preliminary work on the development and validation of a whole blood qPCR classifier that can predict disease course at diagnosis is a great step towards personalized medicine in IBD. The molecular biomarker is currently being investigated in the first-ever biomarker-stratified trial in any inflammatory disease, to determine whether this biomarker can deliver personalized medicine to patients with Crohn's disease.

Artificial intelligence could expand patient access to advanced diagnostics

Study Title: Using Deep Learning for Automated Grading of Endoscopic Disease Severity in Ulcerative Colitis

* R.W. Stidham, University of Michigan, et al.

Endoscopic severity of ulcerative colitis predicts clinical outcomes, making it critical for assessing efficacy of new therapies. However, review requires a high level of experience and there is limited availability of trained reviewers. Interpretation is subjective. This study showed the use of a deep learning algorithm and automated analysis to accurately grade the severity of ulcerative colitis from still images and video colonoscopies as compared with the human reviewers. The study shows the novel use of machine learning to overcome the lack of standardization, a contributing factor in the disparity in patient care. This could substantially improve patient access to disease severity assessments where skilled human reviewers are not available.

All abstracts accepted to the Crohn's & Colitis Congress will be published in Inflammatory Bowel Diseases® (the official journal of the Crohn's & Colitis Foundation) and Gastroenterology (the official journal of the American Gastroenterological Association) on Feb. 7.

Attribution to the Crohn's & Colitis Congress® is requested in all coverage.
-end-
About the Crohn's & Colitis Congress®

The Crohn's & Colitis Congress®, taking place Feb. 7-9, 2019, in Las Vegas, combines the strengths of the nation's leading IBD patient organization, Crohn's & Colitis Foundation, and the premier GI professional association, American Gastroenterological Association (AGA). Together we are committed to convening the greatest minds in IBD to transform patient care. The Crohn's & Colitis Congress is the must-attend meeting for all IBD professionals. Learn more at http://crohnscolitiscongress.org.

About the Crohn's & Colitis Foundation

The Crohn's & Colitis Foundation is the largest non-profit, voluntary, health organization dedicated to finding cures for inflammatory bowel diseases (IBD). The Foundation's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who are affected by these diseases. The Foundation works to fulfill its mission by funding research; providing educational resources for patients and their families, medical professionals, and the public; and furnishing supportive services for those afflicted with IBD. For more information visit http://www.crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org.



About the AGA Institute


The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. http://www.gastro.org. Like AGA on Facebook . Follow us on Twitter @AmerGastroAssn. Check out our videos on YouTube. Join AGA on LinkedIn.

American Gastroenterological Association

Related Inflammatory Bowel Disease Articles:

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).
Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.
Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.
Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.
Inflammatory bowel disease appears to impact risk of Parkinson's disease
Amsterdam, NL, November 14, 2019 - Relatively new research findings indicating that the earliest stages of Parkinson's disease (PD) may occur in the gut have been gaining traction in recent years.
Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.
FODMAPs diet relieves symptoms of inflammatory bowel disease
New research from King's College London has found that a diet low in fermented carbohydrates has improved certain gut symptoms and improved health-related quality of life for sufferers of inflammatory bowel disease (IBD).
The diet-microbiome connection in inflammatory bowel disease
A change in diet is a go-to strategy for treating inflammatory bowel diseases like Crohn's.
Edinburgh is global hotspot for inflammatory bowel disease rates
Edinburgh has some of the highest known rates of inflammatory bowel disease in the world and the figure is expected to rise in the next 10 years.
Medication linked to increased risk of inflammatory bowel disease
Medications that target tumor necrosis factor alpha (TNFα), a protein involved in inflammation, have revolutionized the management of certain autoimmune diseases, but paradoxically, these agents might provoke the development of other autoimmune conditions.
More Inflammatory Bowel Disease News and Inflammatory Bowel Disease Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.